Jocelyn Booth
Regeneron (United States)(US)
Publications by Year
Research Areas
Nonmelanoma Skin Cancer Studies, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,358 cited
- → Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial(2020)462 cited
- → Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing(2020)172 cited
- → Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis(2021)104 cited
- → An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy(2011)87 cited
- → A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6(2024)45 cited
- → Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.(2020)39 cited
- → Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.(2019)32 cited
- → Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).(2019)29 cited
- → High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma(2024)9 cited